l carnitine tmao nature medicine 2013 koeth γ–Butyrobetaine is a pro-atherogenic intermediate in gut microbial metabolism of L-carnitine to A systematic review of TMAO,
A systematic review of TMAO, microRNAs, and the oral gut microbiomes in atherosclerosis and myocardial infarction: mechanistic insights and translational opportunities Journal of Translational Medicine Springer Nature Link Frontiers Gut Microbiota Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target The gutbrain axis and trimethylamine N oxide: an emergent biomarker in neurological diseases ScienceDirect Butyrobetaine Is a Proatherogenic Intermediate in Gut Microbial Metabolism of L Carnitine to TMAO ScienceDirect
Pay in 4 interest-free payments of $6.41 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



